NASDAQ · PTIXW
Protagenic Therapeutics, Inc.
Healthcare · Biotechnology
$0.02
Down-$0.00 (-6.25%)
Updated Aug 15, 2026, 6:44 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 39.52K
- P/E ratio
- -0.32
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 24.02K
- Avg. volume
- 44.2K
Price performance
PTIXW price history
1M range · 0 trading sessions · Daily adjusted prices
PTIXW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest PTIXW news
The latest Smart Investors Daily articles mentioning PTIXW.
Stock researchCompany · Overview
PTIXW research
Overview
Company profile and research snapshot.
Company profile
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
